Literature DB >> 20208571

Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT.

K Ueda1, T Watadani, E Maeda, S Ota, K Kataoka, S Seo, K Kumano, A Hangaishi, T Takahashi, Y Imai, K Ohtomo, M Fukayama, Y Nannya, M Kurokawa.   

Abstract

Late-onset noninfectious pulmonary complications (LONIPCs) are life threatening for allogeneic hematopoietic SCT (allo-HSCT) recipients. However, the impact of LONIPCs on survival has not been properly evaluated and little is known about treatment efficacy. We retrospectively investigated 290 allo-HSCT recipients in our institute and reviewed the clinical aspects of 44 patients who had been diagnosed with LONIPCs. LONIPCs were significantly associated with higher rates of chronic GVHD (P<0001) and nonrelapse mortality (P=0.013), and lower rates of relapse (P=0.009). As a result of these effects, OS was significantly worse in those with LONIPCs (P=0.003). This result differs from a previous report. We then assessed short-term treatment response and final outcome. These results were defined by radiological findings, subjective symptoms, oxygen requirement and survival. Use of inhaled and systemic steroids did not affect either short-term response or final outcomes. However, administration of systemic corticosteroids earlier than at 21 days (median interval of time from onset of symptoms to systemic corticosteroids administration) was associated with a better outcome (P=0.054 for short-term response, and 0.016 for final outcome). Our study indicates that LONIPCs reduce OS, and early intervention with systemic corticosteroids may be effective.

Entities:  

Mesh:

Year:  2010        PMID: 20208571     DOI: 10.1038/bmt.2010.48

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  4 in total

1.  Exploring the possibilities: airspace disease in the postallogeneic haematopoietic stem cell transplant period.

Authors:  Talal Hilal; Zartash Gul
Journal:  BMJ Case Rep       Date:  2015-10-29

2.  Pulmonary hypertension associated with bronchiolitis obliterans after hematopoietic stem cell transplantation.

Authors:  A Pate; S Rotz; M Warren; R Hirsch; M Cash; K C Myers; J El-Bietar; A Nelson; G Wallace; A H Filipovich; J Bleesing; R S Chima; S M Davies; S Jodele; C E Dandoy
Journal:  Bone Marrow Transplant       Date:  2015-10-19       Impact factor: 5.483

3.  Protective role of T-bet and Th1 cytokines in pulmonary graft-versus-host disease and peribronchiolar fibrosis.

Authors:  Kymberly M Gowdy; Julia L Nugent; Tereza Martinu; Erin Potts; Laurie D Snyder; W Michael Foster; Scott M Palmer
Journal:  Am J Respir Cell Mol Biol       Date:  2011-09-29       Impact factor: 6.914

4.  The economic burden of NIPC and BOS following allogeneic HSCT in patients with commercial insurance in the United States.

Authors:  Naomi C Sacks; Bridget E Healey; Sajjad Raza; Philip L Cyr; Gerhard Boerner; Ajay Sheshadri
Journal:  Blood Adv       Date:  2022-03-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.